Centessa Pharmaceuticals (CNTA) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CNTA shares.
View CNTA analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued twelve-month price objectives for Centessa Pharmaceuticals' shares. Their CNTA share price forecasts range from $4.00 to $15.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price.
View analysts price targets for CNTA or view top-rated stocks among Wall Street analysts.

Centessa Pharmaceuticals' stock was trading at $3.10 at the beginning of 2023. Since then, CNTA stock has increased by 96.1% and is now trading at $6.08.
View the best growth stocks for 2023 here.

Centessa Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,300,000 shares, a drop of 29.7% from the August 15th total of 1,850,000 shares. Based on an average daily trading volume, of 162,800 shares, the days-to-cover ratio is presently 8.0 days. Approximately 2.3% of the company's stock are short sold.
View Centessa Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our CNTA earnings forecast.

Centessa Pharmaceuticals plc (NASDAQ:CNTA) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.17.

(CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

Centessa Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNTA."

Centessa Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (2.10%), Affinity Asset Advisors LLC (0.95%), Tanager Wealth Management LLP (0.73%), Woodline Partners LP (0.72%), BlackRock Inc. (0.31%) and Platinum Investment Management Ltd. (0.18%). Insiders that own company stock include (Bermuda) Ltd Gap, Aaron Kantoff, Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Harris Rotman, Iqbal J Hussain, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha, Thomas Templeman and Tia L Bush.
View institutional ownership trends.

Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNTA stock can currently be purchased for approximately $6.08.

Centessa Pharmaceuticals (NASDAQ:CNTA) has a market capitalization of $592.19 million. The company earns $-216,210,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

Centessa Pharmaceuticals' mailing address is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. The official website for the company is www.centessa.com. The company can be reached via phone at 44-73-9178-9784 or via email at investorrelations@centessa.com.